Table 2.
Clinical Outcomes
| Overall | Intensive | Standard | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Sample | Outcome | Events | %/yr (95% CI) |
Events | %/yr (95% CI) |
Events | %/yr (95% CI) | HR (95% CI) |
P |
| All | Primary outcome (any of A-E) | 618 | 2.08 (1.92, 2.25) |
264 | 1.77 (1.57, 2.00) |
354 | 2.40 (2.16, 2.66) |
0.73 (0.63, 0.86) |
<0.001 |
| All | (A) All MI | 242 | 0.80 (0.71, 0.91) |
102 | 0.68 (0.56, 0.82) |
140 | 0.93 (0.79, 1.10) |
0.72 (0.56, 0.93) |
0.01 |
| All | (B) Non-MI ACS | 83 | 0.27 (0.22, 0.34) |
42 | 0.28 (0.20, 0.37) |
41 | 0.27 (0.20, 0.37) |
1.02 (0.66, 1.57) |
0.93 |
| All | (C) All stroke | 147 | 0.49 (0.41, 0.57) |
69 | 0.45 (0.36, 0.58) |
78 | 0.52 (0.41, 0.64) |
0.89 (0.64, 1.23) |
0.48 |
| All | (D) All HF | 173 | 0.57 (0.49, 0.66) |
68 | 0.45 (0.35, 0.57) |
105 | 0.70 (0.58, 0.84) |
0.63 (0.46, 0.86) |
0.003 |
| All | (E) CVD death | 112 | 0.37 (0.31, 0.44) |
41 | 0.27 (0.20, 0.36) |
71 | 0.47 (0.37, 0.59) |
0.57 (0.39, 0.84) |
0.004 |
| All | Non-fatal MI | 240 | 0.80 (0.70, 0.90) |
101 | 0.67 (0.55, 0.81) |
139 | 0.93 (0.78, 1.09) |
0.72 (0.56, 0.93) |
0.01 |
| All | Non-fatal stroke | 144 | 0.48 (0.40, 0.56) |
68 | 0.45 (0.35, 0.57) |
76 | 0.50 (0.40, 0.63) |
0.90 (0.65, 1.25) |
0.53 |
| All | Non-fatal heart failure | 167 | 0.55 (0.47, 0.64) |
66 | 0.43 (0.34, 0.55) |
101 | 0.67 (0.55, 0.81) |
0.64 (0.47, 0.87) |
0.004 |
| All | All deaths | 378 | 1.24 (1.12, 1.37) |
163 | 1.06 (0.91, 1.24) |
215 | 1.41 (1.23, 1.61) |
0.75 (0.61, 0.92) |
0.006 |
| All | Primary or death | 844 | 2.84 (2.65, 3.03) |
370 | 2.47 (2.24, 2.74) |
474 | 3.20 (2.93, 3.50) |
0.77 (0.67, 0.88) |
<0.001 |
| CKD | Primary CKD outcome (any of F-H) | 33 | 0.38 (0.27, 0.54) |
17 | 0.39 (0.24, 0.63) |
16 | 0.37 (0.23, 0.61) |
1.02 (0.51, 2.05) |
0.95 |
| CKD | (F) 50% reduction in eGFR (2x, ≥90 days apart) | 24 | 0.28 (0.19, 0.42) |
12 | 0.28 (0.16, 0.49) |
12 | 0.28 (0.16, 0.49) |
0.97 (0.43, 2.20) |
0.95 |
| CKD | (G) Dialysis | 17 | 0.20 (0.12, 0.32) |
7 | 0.16 (0.08, 0.34) |
10 | 0.23 (0.13, 0.43) |
0.65 (0.23, 1.70) |
0.38 |
| CKD | (H) Kidney transplant | 0 | - | 0 | - | 0 | - | - | |
| CKD | Incident albuminuria (CKD) | 149 | 4.74 (4.04, 5.57) |
64 | 3.93 (3.08, 5.03) |
85 | 5.61 (4.54, 6.94) |
0.71 (0.50, 1.00) |
0.05 |
| Non-CKD | Secondary CKD outcome (non-CKD subsample, any of I-K) | 189 | 0.88 (0.76, 1.02) |
148 | 1.39 (1.18, 1.63) |
41 | 0.38 (0.28, 0.51) |
3.67 (2.62, 5.26) |
<0.001 |
| Non-CKD | (I) 30% reduction in eGFR and <60 (2x, >=90 days apart) | 189 | 0.88 (0.76, 1.02) |
148 | 1.39 (1.18, 1.63) |
41 | 0.38 (0.28, 0.51) |
3.67 (2.62, 5.26) |
<0.001 |
| Non-CKD | (J) Dialysis | 0 | - | 0 | - | 0 | - | - | |
| Non-CKD | (K) Kidney transplant | 0 | - | 0 | - | 0 | - | - | |
| Non-CKD | Incident albuminuria (non-CKD) | 326 | 2.90 (2.60, 3.23) |
142 | 2.54 (2.16, 3.00) |
184 | 3.25 (2.82, 3.76) |
0.77 (0.62, 0.96) |
0.02 |
Final results of pre-specified primary and secondary outcomes from SPRINT. Lewis CE, Fine LJ, Beddhu S, et al. Final cardiovascular and mortality results of a randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2021;384:1921–30